Cholinergic‐dependent cognitive deficits in Parkinson's disease
Identifieur interne : 000813 ( Istex/Corpus ); précédent : 000812; suivant : 000814Cholinergic‐dependent cognitive deficits in Parkinson's disease
Auteurs : Jacques Dubois ; François Danzé ; Bernard Pillon ; Guliana Cusimano ; François Lhermitte ; Yves AgidSource :
- Annals of Neurology [ 0364-5134 ] ; 1987-07.
Abstract
In a double‐blind cross‐over study, the effects of a subthreshold dose of scopolamine (0.25 mg) on memory were compared in 32 control subjects and 32 parkinsonian patients who were without any sign of intellectual and mnemic impairment. Although the scores of the controls in the memory test battery showed no deterioration after the administration of scopolamine, the same dose resulted in significantly reduced memory performance in parkinsonian patients in two tests which involved the recognition of meaningless drawings. The selective vulnerability of parkinsonian subjects without cognitive impairment to a subthreshold dose of scopolamine suggests the existence of an underlying alteration of central cholinergic transmission. The neuropsychological findings in our study agree with postmortem biochemical data, which showed decreased cortical choline acetyltransferase activity in all parkinsonian patients, suggesting the existence of neuronal compensation in parkinsonian patients who are without cognitive impairment.
Url:
DOI: 10.1002/ana.410220108
Links to Exploration step
ISTEX:A2ACEB2250FD5365E3C81C0ECCCD3AF2E8CB07A0Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cholinergic‐dependent cognitive deficits in Parkinson's disease</title><author><name sortKey="Dubois, Jacques" sort="Dubois, Jacques" uniqKey="Dubois J" first="Jacques" last="Dubois">Jacques Dubois</name><affiliation><mods:affiliation>The Clinique de Neurologie et Neuropsychologie and INSERM U289, Hôpital de la Pitié‐Salpêtrière, 97 Bd de l'Hôpital, 75013 Paris, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Clinique de Neurologie et Neuropsychologie, Hôpital de la Salpêtriére, 47, Bd de l'Hôpital, 75651 Paris Cedex 13, France</mods:affiliation></affiliation></author><author><name sortKey="Danze, Francois" sort="Danze, Francois" uniqKey="Danze F" first="François" last="Danzé">François Danzé</name><affiliation><mods:affiliation>The Clinique de Neurologie et Neuropsychologie and INSERM U289, Hôpital de la Pitié‐Salpêtrière, 97 Bd de l'Hôpital, 75013 Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Pillon, Bernard" sort="Pillon, Bernard" uniqKey="Pillon B" first="Bernard" last="Pillon">Bernard Pillon</name><affiliation><mods:affiliation>The Clinique de Neurologie et Neuropsychologie and INSERM U289, Hôpital de la Pitié‐Salpêtrière, 97 Bd de l'Hôpital, 75013 Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Cusimano, Guliana" sort="Cusimano, Guliana" uniqKey="Cusimano G" first="Guliana" last="Cusimano">Guliana Cusimano</name><affiliation><mods:affiliation>The Clinique de Neurologie et Neuropsychologie and INSERM U289, Hôpital de la Pitié‐Salpêtrière, 97 Bd de l'Hôpital, 75013 Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Lhermitte, Francois" sort="Lhermitte, Francois" uniqKey="Lhermitte F" first="François" last="Lhermitte">François Lhermitte</name><affiliation><mods:affiliation>The Clinique de Neurologie et Neuropsychologie and INSERM U289, Hôpital de la Pitié‐Salpêtrière, 97 Bd de l'Hôpital, 75013 Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Agid, Yves" sort="Agid, Yves" uniqKey="Agid Y" first="Yves" last="Agid">Yves Agid</name><affiliation><mods:affiliation>The Clinique de Neurologie et Neuropsychologie and INSERM U289, Hôpital de la Pitié‐Salpêtrière, 97 Bd de l'Hôpital, 75013 Paris, France</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A2ACEB2250FD5365E3C81C0ECCCD3AF2E8CB07A0</idno><date when="1987" year="1987">1987</date><idno type="doi">10.1002/ana.410220108</idno><idno type="url">https://api.istex.fr/document/A2ACEB2250FD5365E3C81C0ECCCD3AF2E8CB07A0/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000813</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000813</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Cholinergic‐dependent cognitive deficits in Parkinson's disease</title><author><name sortKey="Dubois, Jacques" sort="Dubois, Jacques" uniqKey="Dubois J" first="Jacques" last="Dubois">Jacques Dubois</name><affiliation><mods:affiliation>The Clinique de Neurologie et Neuropsychologie and INSERM U289, Hôpital de la Pitié‐Salpêtrière, 97 Bd de l'Hôpital, 75013 Paris, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Clinique de Neurologie et Neuropsychologie, Hôpital de la Salpêtriére, 47, Bd de l'Hôpital, 75651 Paris Cedex 13, France</mods:affiliation></affiliation></author><author><name sortKey="Danze, Francois" sort="Danze, Francois" uniqKey="Danze F" first="François" last="Danzé">François Danzé</name><affiliation><mods:affiliation>The Clinique de Neurologie et Neuropsychologie and INSERM U289, Hôpital de la Pitié‐Salpêtrière, 97 Bd de l'Hôpital, 75013 Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Pillon, Bernard" sort="Pillon, Bernard" uniqKey="Pillon B" first="Bernard" last="Pillon">Bernard Pillon</name><affiliation><mods:affiliation>The Clinique de Neurologie et Neuropsychologie and INSERM U289, Hôpital de la Pitié‐Salpêtrière, 97 Bd de l'Hôpital, 75013 Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Cusimano, Guliana" sort="Cusimano, Guliana" uniqKey="Cusimano G" first="Guliana" last="Cusimano">Guliana Cusimano</name><affiliation><mods:affiliation>The Clinique de Neurologie et Neuropsychologie and INSERM U289, Hôpital de la Pitié‐Salpêtrière, 97 Bd de l'Hôpital, 75013 Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Lhermitte, Francois" sort="Lhermitte, Francois" uniqKey="Lhermitte F" first="François" last="Lhermitte">François Lhermitte</name><affiliation><mods:affiliation>The Clinique de Neurologie et Neuropsychologie and INSERM U289, Hôpital de la Pitié‐Salpêtrière, 97 Bd de l'Hôpital, 75013 Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Agid, Yves" sort="Agid, Yves" uniqKey="Agid Y" first="Yves" last="Agid">Yves Agid</name><affiliation><mods:affiliation>The Clinique de Neurologie et Neuropsychologie and INSERM U289, Hôpital de la Pitié‐Salpêtrière, 97 Bd de l'Hôpital, 75013 Paris, France</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>American Neurological Association</publisher><pubPlace>Boston</pubPlace><date type="published" when="1987-07">1987-07</date><biblScope unit="volume">22</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="26">26</biblScope><biblScope unit="page" to="30">30</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">A2ACEB2250FD5365E3C81C0ECCCD3AF2E8CB07A0</idno><idno type="DOI">10.1002/ana.410220108</idno><idno type="ArticleID">ANA410220108</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In a double‐blind cross‐over study, the effects of a subthreshold dose of scopolamine (0.25 mg) on memory were compared in 32 control subjects and 32 parkinsonian patients who were without any sign of intellectual and mnemic impairment. Although the scores of the controls in the memory test battery showed no deterioration after the administration of scopolamine, the same dose resulted in significantly reduced memory performance in parkinsonian patients in two tests which involved the recognition of meaningless drawings. The selective vulnerability of parkinsonian subjects without cognitive impairment to a subthreshold dose of scopolamine suggests the existence of an underlying alteration of central cholinergic transmission. The neuropsychological findings in our study agree with postmortem biochemical data, which showed decreased cortical choline acetyltransferase activity in all parkinsonian patients, suggesting the existence of neuronal compensation in parkinsonian patients who are without cognitive impairment.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Dr. Dubois</name><affiliations><json:string>The Clinique de Neurologie et Neuropsychologie and INSERM U289, Hôpital de la Pitié‐Salpêtrière, 97 Bd de l'Hôpital, 75013 Paris, France</json:string><json:string>Clinique de Neurologie et Neuropsychologie, Hôpital de la Salpêtriére, 47, Bd de l'Hôpital, 75651 Paris Cedex 13, France</json:string></affiliations></json:item><json:item><name>François Danzé</name><affiliations><json:string>The Clinique de Neurologie et Neuropsychologie and INSERM U289, Hôpital de la Pitié‐Salpêtrière, 97 Bd de l'Hôpital, 75013 Paris, France</json:string></affiliations></json:item><json:item><name>Bernard Pillon PhD</name><affiliations><json:string>The Clinique de Neurologie et Neuropsychologie and INSERM U289, Hôpital de la Pitié‐Salpêtrière, 97 Bd de l'Hôpital, 75013 Paris, France</json:string></affiliations></json:item><json:item><name>Guliana Cusimano</name><affiliations><json:string>The Clinique de Neurologie et Neuropsychologie and INSERM U289, Hôpital de la Pitié‐Salpêtrière, 97 Bd de l'Hôpital, 75013 Paris, France</json:string></affiliations></json:item><json:item><name>François Lhermitte</name><affiliations><json:string>The Clinique de Neurologie et Neuropsychologie and INSERM U289, Hôpital de la Pitié‐Salpêtrière, 97 Bd de l'Hôpital, 75013 Paris, France</json:string></affiliations></json:item><json:item><name>Yves Agid PhD</name><affiliations><json:string>The Clinique de Neurologie et Neuropsychologie and INSERM U289, Hôpital de la Pitié‐Salpêtrière, 97 Bd de l'Hôpital, 75013 Paris, France</json:string></affiliations></json:item></author><articleId><json:string>ANA410220108</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>In a double‐blind cross‐over study, the effects of a subthreshold dose of scopolamine (0.25 mg) on memory were compared in 32 control subjects and 32 parkinsonian patients who were without any sign of intellectual and mnemic impairment. Although the scores of the controls in the memory test battery showed no deterioration after the administration of scopolamine, the same dose resulted in significantly reduced memory performance in parkinsonian patients in two tests which involved the recognition of meaningless drawings. The selective vulnerability of parkinsonian subjects without cognitive impairment to a subthreshold dose of scopolamine suggests the existence of an underlying alteration of central cholinergic transmission. The neuropsychological findings in our study agree with postmortem biochemical data, which showed decreased cortical choline acetyltransferase activity in all parkinsonian patients, suggesting the existence of neuronal compensation in parkinsonian patients who are without cognitive impairment.</abstract><qualityIndicators><score>4.725</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 828 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1028</abstractCharCount><pdfWordCount>3045</pdfWordCount><pdfCharCount>19903</pdfCharCount><pdfPageCount>5</pdfPageCount><abstractWordCount>140</abstractWordCount></qualityIndicators><title>Cholinergic‐dependent cognitive deficits in Parkinson's disease</title><refBibs><json:item><author><json:item><name>Y Agid</name></json:item><json:item><name>M Ruberg</name></json:item><json:item><name>B Dubois</name></json:item><json:item><name>F Javoy‐Agid</name></json:item></author><host><volume>40</volume><pages><last>218</last><first>211</first></pages><author></author><title>Parkinson‐Specific Motor and Mental Disorders</title></host><title>Biochemical substrates of mental disturbances in Parkinson's disease</title></json:item><json:item><author><json:item><name>ML Albert</name></json:item></author><host><pages><last>180</last><first>173</first></pages><author></author><title>Alzheimer's Disease: Senile Dementia and Related Disorders. (Vol 7, Aging)</title></host><title>Subcortical dementia</title></json:item><json:item><author><json:item><name>F Boller</name></json:item><json:item><name>T Mizutani</name></json:item><json:item><name>U Roessmann</name></json:item><json:item><name>P Gambetti</name></json:item></author><host><volume>7</volume><pages><last>335</last><first>329</first></pages><author></author><title>Ann Neurol</title></host><title>Parkinson disease, dementia, and Alzheimer disease: clinicopathological correlations</title></json:item><json:item><author><json:item><name>GG Celesia</name></json:item><json:item><name>WM Wanamaker</name></json:item></author><host><volume>33</volume><pages><last>583</last><first>577</first></pages><author></author><title>Dis Nerv Syst</title></host><title>Psychiatric disturbances in Parkinson's disease</title></json:item><json:item><author><json:item><name>TJ Crow</name></json:item></author><host><volume>49</volume><pages><last>327</last><first>322</first></pages><author></author><title>Br J Pharmacol</title></host><title>Grove‐White I: An analysis of the learning deficit following hyoscine on human learning capacity</title></json:item><json:item><author><json:item><name>J De Ajuriaguerra</name></json:item></author><host><pages><last>351</last><first>327</first></pages><author></author><title>Monoamines, Noyaux Gris Centraux et Syndrome de Parkinson</title></host><title>Etude psychopathologique des parkinsoniens</title></json:item><json:item><author><json:item><name>Y De Smet</name></json:item><json:item><name>M Ruberg</name></json:item><json:item><name>M Serdaru</name></json:item></author><host><volume>45</volume><pages><last>1164</last><first>1161</first></pages><author></author><title>J Neurol Neurosurg Psychiatry</title></host><title>Confusion, dementia and anticholinergics in Parkinson's disease</title></json:item><json:item><author><json:item><name>JA Deutsch</name></json:item></author><host><volume>174</volume><pages><last>794</last><first>788</first></pages><author></author><title>Science</title></host><title>The cholinergic synapse and the site of memory</title></json:item><json:item><author><json:item><name>LJ Doshay</name></json:item><json:item><name>K Constable</name></json:item><json:item><name>A Zeir</name></json:item></author><host><volume>154</volume><pages><last>1336</last><first>1334</first></pages><author></author><title>JAMA</title></host><title>Five‐year follow‐up of treatment with trihexyphenidyl (Artane)</title></json:item><json:item><author><json:item><name>DA Drachman</name></json:item></author><host><volume>27</volume><pages><last>790</last><first>783</first></pages><author></author><title>Neurology</title></host><title>Memory and cognitive function in man: does the cholinergic system have a specific role?</title></json:item><json:item><author><json:item><name>DA Drachman</name></json:item><json:item><name>J Leavitt</name></json:item></author><host><volume>30</volume><pages><last>121</last><first>113</first></pages><author></author><title>Arch Neurol</title></host><title>Human memory and the cholinergic system</title></json:item><json:item><author><json:item><name>B Dubois</name></json:item><json:item><name>JJ Hauw</name></json:item><json:item><name>M Ruberg</name></json:item></author><host><volume>141</volume><pages><last>193</last><first>184</first></pages><author></author><title>Rev Neurol</title></host><title>Demence et maladie de Parkinson: correlations biochimiques et anatomo‐cliniques</title></json:item><json:item><author><json:item><name>B Dubois</name></json:item><json:item><name>W Mayo</name></json:item><json:item><name>F Agid</name></json:item></author><host><volume>338</volume><pages><last>258</last><first>249</first></pages><author></author><title>Brain Res</title></host><title>Profound disturbances of spontaneous and learned behaviors following lesions of the nucleus basalis magnocellularis in the rat</title></json:item><json:item><author><json:item><name>B Dubois</name></json:item><json:item><name>M Ruberg</name></json:item><json:item><name>F Javoy‐Agid</name></json:item></author><host><volume>288</volume><pages><last>218</last><first>213</first></pages><author></author><title>Brain Res</title></host><title>A subcorticocortical cholinergic system is affected in Parkinson's disease</title></json:item><json:item><author><json:item><name>AM Hakim</name></json:item><json:item><name>G Mathieson</name></json:item></author><host><volume>29</volume><pages><last>1214</last><first>1209</first></pages><author></author><title>Neurology</title></host><title>Dementia in Parkinson disease: a neuropathologic study</title></json:item><json:item><author><json:item><name>SD Iversen</name></json:item></author><host><volume>7</volume><pages><last>349</last><first>321</first></pages><author></author><title>Monoamine Innervation of Cerebral Cortex</title></host><title>Cortical monoamines and behavior</title></json:item><json:item><author><json:item><name>BJ Knowlton</name></json:item><json:item><name>GL Wenk</name></json:item><json:item><name>DS Olton</name></json:item><json:item><name>JT Coyle</name></json:item></author><host><volume>345</volume><pages><last>321</last><first>315</first></pages><author></author><title>Brain Res</title></host><title>Basal forebrain lesions produce a dissociation of trial‐dependent and trialindependent memory performance</title></json:item><json:item><author><json:item><name>F Lhermitte</name></json:item><json:item><name>JL Signoret</name></json:item></author><host><volume>126</volume><pages><last>178</last><first>161</first></pages><author></author><title>Rev Neurol</title></host><title>Analyse neuropsychologique et différenciation des syndromes amnésiques</title></json:item><json:item><host><author></author><title>Luria A:Higher Cortical Functions in Man.New York, Basic Books,1966</title></host></json:item><json:item><author><json:item><name>R Mayeux</name></json:item><json:item><name>Y Stern</name></json:item></author><host><pages><last>227</last><first>211</first></pages><author></author><title>The Dementias</title></host><title>Intellectual dysfunction and dementia in Parkinson's disease</title></json:item><json:item><author><json:item><name>EK Perry</name></json:item><json:item><name>M Curtis</name></json:item><json:item><name>DJ Dick</name></json:item></author><host><volume>48</volume><pages><last>421</last><first>413</first></pages><author></author><title>J Neurol Neurosurg Psychiatry</title></host><title>Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease</title></json:item><json:item><author><json:item><name>B Pillon</name></json:item><json:item><name>B Dubois</name></json:item><json:item><name>F Lhermitte</name></json:item><json:item><name>Y Agid</name></json:item></author><host><volume>36</volume><pages><last>1186</last><first>1179</first></pages><author></author><title>Neurology</title></host><title>Heterogeneity of cognitive impairment in progressive supranuclear palsy, Parkinson's disease and Alzheimer's disease</title></json:item><json:item><author><json:item><name>MN Rossor</name></json:item><json:item><name>NJ Garrett</name></json:item><json:item><name>AL Johnson</name></json:item></author><host><volume>105</volume><pages><last>330</last><first>313</first></pages><author></author><title>Brain</title></host><title>A postmortem study of the cholinergic and GABA systems in senile dementia</title></json:item><json:item><author><json:item><name>M Ruberg</name></json:item><json:item><name>Y Agid</name></json:item></author><host><author></author><title>Handbook of Psychopharmacology, Vol 20: Psychopharmacology of the Ageing Nervous System</title></host><title>Dementia in Parkinson's disease</title></json:item><json:item><author><json:item><name>M Ruberg</name></json:item><json:item><name>A Ploska</name></json:item><json:item><name>F Javoy‐Agid</name></json:item><json:item><name>Y Agid</name></json:item></author><host><volume>232</volume><pages><last>139</last><first>129</first></pages><author></author><title>Brain Res</title></host><title>Muscarinic binding and choline acetyltransferase activity in Parkinson subject with reference to dementia</title></json:item><json:item><author><json:item><name>M Sadeh</name></json:item><json:item><name>J Braham</name></json:item><json:item><name>M Modan</name></json:item></author><host><volume>39</volume><pages><last>667</last><first>666</first></pages><author></author><title>Arch Neurol</title></host><title>Effects of anticholinergic drugs on memory in Parkinson's disease</title></json:item><json:item><author><json:item><name>DJ Safer</name></json:item><json:item><name>RP Allen</name></json:item></author><host><volume>3</volume><pages><last>355</last><first>347</first></pages><author></author><title>Biol Psychiatry</title></host><title>The central effects of scopolamine in man</title></json:item><json:item><author><json:item><name>H Simon</name></json:item><json:item><name>B Scatton</name></json:item><json:item><name>M Le Moal</name></json:item></author><host><volume>286</volume><pages><last>151</last><first>150</first></pages><author></author><title>Nature</title></host><title>Dopaminergic A10 neurones are involved in cognitive functions</title></json:item><json:item><author><json:item><name>N Sitaram</name></json:item><json:item><name>H Weingartner</name></json:item><json:item><name>JC Gillin</name></json:item></author><host><volume>201</volume><pages><last>276</last><first>274</first></pages><author></author><title>Science</title></host><title>Human serial learning: enhancement with arecholine and choline and impairment with scopolamine</title></json:item><json:item><author><json:item><name>DA Stephens</name></json:item></author><host><volume>113</volume><pages><last>218</last><first>213</first></pages><author></author><title>Br J Psychiatry</title></host><title>Psychotic effects of benzhexol hydrochloride (Artane)</title></json:item><json:item><author><json:item><name>Y Stern</name></json:item><json:item><name>JW Langston</name></json:item></author><host><volume>35</volume><pages><last>1509</last><first>1506</first></pages><author></author><title>Neurology</title></host><title>Intellectual changes in patients with MPTP‐induced parkinsonism</title></json:item><json:item><author><json:item><name>Y Stern</name></json:item><json:item><name>R Mayeux</name></json:item><json:item><name>J Rosen</name></json:item><json:item><name>J Ilson</name></json:item></author><host><volume>46</volume><pages><last>151</last><first>145</first></pages><author></author><title>J Neurol Neurosurg Psychiatry</title></host><title>Perceptual motor dysfunction in Parkinson's disease: a deficit in sequential and predictive voluntary movement</title></json:item><json:item><author><json:item><name>GA Talland</name></json:item></author><host><volume>135</volume><pages><last>205</last><first>196</first></pages><author></author><title>J Nerv Ment Dis</title></host><title>Cognitive function in Parkinson's disease</title></json:item><json:item><author><json:item><name>RS Wilson</name></json:item><json:item><name>AW Kaszniak</name></json:item><json:item><name>HL Klawans</name></json:item><json:item><name>DC Garron</name></json:item></author><host><volume>16</volume><pages><last>72</last><first>67</first></pages><author></author><title>Cortex</title></host><title>Highspeed memory scanning in parkinsonism</title></json:item></refBibs><genre><json:string>article</json:string></genre><host><volume>22</volume><publisherId><json:string>ANA</json:string></publisherId><pages><total>5</total><last>30</last><first>26</first></pages><issn><json:string>0364-5134</json:string></issn><issue>1</issue><subject><json:item><value>Original Article</value></json:item></subject><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8249</json:string></eissn><title>Annals of Neurology</title><doi><json:string>10.1002/(ISSN)1531-8249</json:string></doi></host><categories><wos><json:string>science</json:string><json:string>neurosciences</json:string><json:string>clinical neurology</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>neurology & neurosurgery</json:string></scienceMetrix></categories><publicationDate>1987</publicationDate><copyrightDate>1987</copyrightDate><doi><json:string>10.1002/ana.410220108</json:string></doi><id>A2ACEB2250FD5365E3C81C0ECCCD3AF2E8CB07A0</id><score>0.24245374</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/A2ACEB2250FD5365E3C81C0ECCCD3AF2E8CB07A0/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/A2ACEB2250FD5365E3C81C0ECCCD3AF2E8CB07A0/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/A2ACEB2250FD5365E3C81C0ECCCD3AF2E8CB07A0/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Cholinergic‐dependent cognitive deficits in Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>American Neurological Association</publisher><pubPlace>Boston</pubPlace><availability><p>Copyright © 1987 American Neurological Association</p></availability><date>1987</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Cholinergic‐dependent cognitive deficits in Parkinson's disease</title><author xml:id="author-1"><persName><surname>Dubois</surname></persName><roleName type="degree">Dr.</roleName><note type="biography">MD</note><affiliation>MD</affiliation><affiliation>The Clinique de Neurologie et Neuropsychologie and INSERM U289, Hôpital de la Pitié‐Salpêtrière, 97 Bd de l'Hôpital, 75013 Paris, France</affiliation><affiliation>Clinique de Neurologie et Neuropsychologie, Hôpital de la Salpêtriére, 47, Bd de l'Hôpital, 75651 Paris Cedex 13, France</affiliation></author><author xml:id="author-2"><persName><forename type="first">François</forename><surname>Danzé</surname></persName><note type="biography">MD</note><affiliation>MD</affiliation><affiliation>The Clinique de Neurologie et Neuropsychologie and INSERM U289, Hôpital de la Pitié‐Salpêtrière, 97 Bd de l'Hôpital, 75013 Paris, France</affiliation></author><author xml:id="author-3"><persName><forename type="first">Bernard</forename><surname>Pillon</surname></persName><roleName type="degree">PhD</roleName><affiliation>The Clinique de Neurologie et Neuropsychologie and INSERM U289, Hôpital de la Pitié‐Salpêtrière, 97 Bd de l'Hôpital, 75013 Paris, France</affiliation></author><author xml:id="author-4"><persName><forename type="first">Guliana</forename><surname>Cusimano</surname></persName><note type="biography">MD</note><affiliation>MD</affiliation><affiliation>The Clinique de Neurologie et Neuropsychologie and INSERM U289, Hôpital de la Pitié‐Salpêtrière, 97 Bd de l'Hôpital, 75013 Paris, France</affiliation></author><author xml:id="author-5"><persName><forename type="first">François</forename><surname>Lhermitte</surname></persName><note type="biography">MD</note><affiliation>MD</affiliation><affiliation>The Clinique de Neurologie et Neuropsychologie and INSERM U289, Hôpital de la Pitié‐Salpêtrière, 97 Bd de l'Hôpital, 75013 Paris, France</affiliation></author><author xml:id="author-6"><persName><forename type="first">Yves</forename><surname>Agid</surname></persName><roleName type="degree">PhD</roleName><note type="biography">MD</note><affiliation>MD</affiliation><affiliation>The Clinique de Neurologie et Neuropsychologie and INSERM U289, Hôpital de la Pitié‐Salpêtrière, 97 Bd de l'Hôpital, 75013 Paris, France</affiliation></author></analytic><monogr><title level="j">Annals of Neurology</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="pISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><idno type="DOI">10.1002/(ISSN)1531-8249</idno><imprint><publisher>American Neurological Association</publisher><pubPlace>Boston</pubPlace><date type="published" when="1987-07"></date><biblScope unit="volume">22</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="26">26</biblScope><biblScope unit="page" to="30">30</biblScope></imprint></monogr><idno type="istex">A2ACEB2250FD5365E3C81C0ECCCD3AF2E8CB07A0</idno><idno type="DOI">10.1002/ana.410220108</idno><idno type="ArticleID">ANA410220108</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1987</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>In a double‐blind cross‐over study, the effects of a subthreshold dose of scopolamine (0.25 mg) on memory were compared in 32 control subjects and 32 parkinsonian patients who were without any sign of intellectual and mnemic impairment. Although the scores of the controls in the memory test battery showed no deterioration after the administration of scopolamine, the same dose resulted in significantly reduced memory performance in parkinsonian patients in two tests which involved the recognition of meaningless drawings. The selective vulnerability of parkinsonian subjects without cognitive impairment to a subthreshold dose of scopolamine suggests the existence of an underlying alteration of central cholinergic transmission. The neuropsychological findings in our study agree with postmortem biochemical data, which showed decreased cortical choline acetyltransferase activity in all parkinsonian patients, suggesting the existence of neuronal compensation in parkinsonian patients who are without cognitive impairment.</p></abstract><textClass><keywords scheme="Journal Subject"><list><head>article-category</head><item><term>Original Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1986-07-24">Received</change><change when="1986-11-30">Registration</change><change when="1987-07">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/A2ACEB2250FD5365E3C81C0ECCCD3AF2E8CB07A0/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>American Neurological Association</publisherName><publisherLoc>Boston</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8249</doi><issn type="print">0364-5134</issn><issn type="electronic">1531-8249</issn><idGroup><id type="product" value="ANA"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="ANNALS OF NEUROLOGY">Annals of Neurology</title><title type="short">Ann Neurol.</title></titleGroup></publicationMeta><publicationMeta level="part" position="10"><doi origin="wiley" registered="yes">10.1002/ana.v22:1</doi><numberingGroup><numbering type="journalVolume" number="22">22</numbering><numbering type="journalIssue">1</numbering></numberingGroup><coverDate startDate="1987-07">July 1987</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="8" status="forIssue"><doi origin="wiley" registered="yes">10.1002/ana.410220108</doi><idGroup><id type="unit" value="ANA410220108"></id></idGroup><countGroup><count type="pageTotal" number="5"></count></countGroup><titleGroup><title type="articleCategory">Original Article</title><title type="tocHeading1">Original Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 1987 American Neurological Association</copyright><eventGroup><event type="manuscriptReceived" date="1986-07-24"></event><event type="manuscriptRevised" date="1986-11-06"></event><event type="manuscriptAccepted" date="1986-11-30"></event><event type="firstOnline" date="2004-10-08"></event><event type="publishedOnlineFinalForm" date="2004-10-08"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:HeaderRef result:HeaderRef" date="2011-02-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-03"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-14"></event></eventGroup><numberingGroup><numbering type="pageFirst">26</numbering><numbering type="pageLast">30</numbering></numberingGroup><correspondenceTo>Clinique de Neurologie et Neuropsychologie, Hôpital de la Salpêtriére, 47, Bd de l'Hôpital, 75651 Paris Cedex 13, France</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:ANA.ANA410220108.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="3"></count><count type="referenceTotal" number="34"></count></countGroup><titleGroup><title type="main" xml:lang="en">Cholinergic‐dependent cognitive deficits in Parkinson's disease</title><title type="short" xml:lang="en">Cholinergic‐Dependent Cognitive Deficits in Parkinsonism</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><honorifics>Dr.</honorifics><givenNames>Bruno</givenNames><familyName>Dubois</familyName></personName><jobTitle>MD</jobTitle></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>François</givenNames><familyName>Danzé</familyName></personName><jobTitle>MD</jobTitle></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Bernard</givenNames><familyName>Pillon</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Guliana</givenNames><familyName>Cusimano</familyName></personName><jobTitle>MD</jobTitle></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1"><personName><givenNames>François</givenNames><familyName>Lhermitte</familyName></personName><jobTitle>MD</jobTitle></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Yves</givenNames><familyName>Agid</familyName><degrees>PhD</degrees></personName><jobTitle>MD</jobTitle></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="FR" type="organization"><unparsedAffiliation>The Clinique de Neurologie et Neuropsychologie and INSERM U289, Hôpital de la Pitié‐Salpêtrière, 97 Bd de l'Hôpital, 75013 Paris, France</unparsedAffiliation></affiliation></affiliationGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>In a double‐blind cross‐over study, the effects of a subthreshold dose of scopolamine (0.25 mg) on memory were compared in 32 control subjects and 32 parkinsonian patients who were without any sign of intellectual and mnemic impairment. Although the scores of the controls in the memory test battery showed no deterioration after the administration of scopolamine, the same dose resulted in significantly reduced memory performance in parkinsonian patients in two tests which involved the recognition of meaningless drawings. The selective vulnerability of parkinsonian subjects without cognitive impairment to a subthreshold dose of scopolamine suggests the existence of an underlying alteration of central cholinergic transmission. The neuropsychological findings in our study agree with postmortem biochemical data, which showed decreased cortical choline acetyltransferase activity in all parkinsonian patients, suggesting the existence of neuronal compensation in parkinsonian patients who are without cognitive impairment.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Cholinergic‐dependent cognitive deficits in Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Cholinergic‐Dependent Cognitive Deficits in Parkinsonism</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Cholinergic‐dependent cognitive deficits in Parkinson's disease</title></titleInfo><name type="personal"><namePart type="termsOfAddress">Dr.</namePart><namePart type="family">Dubois</namePart><affiliation>The Clinique de Neurologie et Neuropsychologie and INSERM U289, Hôpital de la Pitié‐Salpêtrière, 97 Bd de l'Hôpital, 75013 Paris, France</affiliation><affiliation>Clinique de Neurologie et Neuropsychologie, Hôpital de la Salpêtriére, 47, Bd de l'Hôpital, 75651 Paris Cedex 13, France</affiliation><role><roleTerm type="text">author</roleTerm></role><description>MD</description></name><name type="personal"><namePart type="given">François</namePart><namePart type="family">Danzé</namePart><affiliation>The Clinique de Neurologie et Neuropsychologie and INSERM U289, Hôpital de la Pitié‐Salpêtrière, 97 Bd de l'Hôpital, 75013 Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role><description>MD</description></name><name type="personal"><namePart type="given">Bernard</namePart><namePart type="family">Pillon</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>The Clinique de Neurologie et Neuropsychologie and INSERM U289, Hôpital de la Pitié‐Salpêtrière, 97 Bd de l'Hôpital, 75013 Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Guliana</namePart><namePart type="family">Cusimano</namePart><affiliation>The Clinique de Neurologie et Neuropsychologie and INSERM U289, Hôpital de la Pitié‐Salpêtrière, 97 Bd de l'Hôpital, 75013 Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role><description>MD</description></name><name type="personal"><namePart type="given">François</namePart><namePart type="family">Lhermitte</namePart><affiliation>The Clinique de Neurologie et Neuropsychologie and INSERM U289, Hôpital de la Pitié‐Salpêtrière, 97 Bd de l'Hôpital, 75013 Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role><description>MD</description></name><name type="personal"><namePart type="given">Yves</namePart><namePart type="family">Agid</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>The Clinique de Neurologie et Neuropsychologie and INSERM U289, Hôpital de la Pitié‐Salpêtrière, 97 Bd de l'Hôpital, 75013 Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role><description>MD</description></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>American Neurological Association</publisher><place><placeTerm type="text">Boston</placeTerm></place><dateIssued encoding="w3cdtf">1987-07</dateIssued><dateCaptured encoding="w3cdtf">1986-07-24</dateCaptured><dateValid encoding="w3cdtf">1986-11-30</dateValid><copyrightDate encoding="w3cdtf">1987</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">3</extent><extent unit="references">34</extent></physicalDescription><abstract lang="en">In a double‐blind cross‐over study, the effects of a subthreshold dose of scopolamine (0.25 mg) on memory were compared in 32 control subjects and 32 parkinsonian patients who were without any sign of intellectual and mnemic impairment. Although the scores of the controls in the memory test battery showed no deterioration after the administration of scopolamine, the same dose resulted in significantly reduced memory performance in parkinsonian patients in two tests which involved the recognition of meaningless drawings. The selective vulnerability of parkinsonian subjects without cognitive impairment to a subthreshold dose of scopolamine suggests the existence of an underlying alteration of central cholinergic transmission. The neuropsychological findings in our study agree with postmortem biochemical data, which showed decreased cortical choline acetyltransferase activity in all parkinsonian patients, suggesting the existence of neuronal compensation in parkinsonian patients who are without cognitive impairment.</abstract><relatedItem type="host"><titleInfo><title>Annals of Neurology</title></titleInfo><titleInfo type="abbreviated"><title>Ann Neurol.</title></titleInfo><genre type="journal">journal</genre><subject><genre>article-category</genre><topic>Original Article</topic></subject><identifier type="ISSN">0364-5134</identifier><identifier type="eISSN">1531-8249</identifier><identifier type="DOI">10.1002/(ISSN)1531-8249</identifier><identifier type="PublisherID">ANA</identifier><part><date>1987</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>26</start><end>30</end><total>5</total></extent></part></relatedItem><identifier type="istex">A2ACEB2250FD5365E3C81C0ECCCD3AF2E8CB07A0</identifier><identifier type="DOI">10.1002/ana.410220108</identifier><identifier type="ArticleID">ANA410220108</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 1987 American Neurological Association</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>American Neurological Association</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000813 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000813 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:A2ACEB2250FD5365E3C81C0ECCCD3AF2E8CB07A0
|texte= Cholinergic‐dependent cognitive deficits in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.29. |  |